ANNE TSAO, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas L2712
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about ANNE TSAO at radaris.comName
Address
Phone
2210 Hollow Shore St, Pearland, TX 77584
8181 El Mundo St #901, Houston, TX 77054
2210 Hollow Shore St, Pearland, TX 77584
Organization information
See more information about ANNE TSAO at bizstanding.comAnne Tsao MD
1515 Holcombe Blvd, Houston, TX 77030
Industry:
Internist
Phone:
(713) 792-6363 (Phone)
Anne Szu-I Tsao
Professional information
See more information about ANNE TSAO at trustoria.com
Anne Szu-I Tsao, Houston TX
Anne Szu-I Tsao, Houston TX
Specialties:
Internal Medicine, Medical Oncology, Plastic Surgery Within the Head and Neck
Work:
M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
University of Chicago (1998)
Dr. Anne Tsao, Houston TX - MD (Doctor of Medicine)
Dr. Anne Tsao, Houston TX - MD (Doctor of Medicine)
Age:
50
Address:
1515 Holcombe Blvd, Houston 77030
MD Andrsn Cncr Cntr Thrcc Onclg
1515 Holcombe Blvd SUITE 9, Houston 77030
(713) 792-6110 (Phone)
1515 Holcombe Blvd, Houston 77030
MD Andrsn Cncr Cntr Thrcc Onclg
1515 Holcombe Blvd SUITE 9, Houston 77030
(713) 792-6110 (Phone)
MD Andrsn Cncr Cntr Thrcc Onclg
1515 Holcombe Blvd SUITE 9, Houston 77030
(713) 792-6110 (Phone)
1515 Holcombe Blvd, Houston 77030
MD Andrsn Cncr Cntr Thrcc Onclg
1515 Holcombe Blvd SUITE 9, Houston 77030
(713) 792-6110 (Phone)
Education:
Medical Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1998
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1998
Biomarkers For Response To Tyrosine Kinase Pathway Inhibitors In Cancer
Biomarkers For Response To Tyrosine Kinase Pathway Inhibitors In Cancer
US Patent:
2013023, Sep 5, 2013
Filed:
Feb 4, 2013
Appl. No.:
13/758728
Inventors:
Ignacio I. WISTUBA - Houston TX, US
Monique B. NILSSON - Sugar Land TX, US
Lauren A. BYERS - Houston TX, US
Ximing TANG - Houston TX, US
Fei YANG - Houston TX, US
Edward KIM - Houston TX, US
Anne S. TSAO - Houston TX, US
Scott M. LIPPMAN - Houston TX, US
Waun Ki HONG - Houston TX, US
Roy S. HERBST - Houston TX, US
Monique B. NILSSON - Sugar Land TX, US
Lauren A. BYERS - Houston TX, US
Ximing TANG - Houston TX, US
Fei YANG - Houston TX, US
Edward KIM - Houston TX, US
Anne S. TSAO - Houston TX, US
Scott M. LIPPMAN - Houston TX, US
Waun Ki HONG - Houston TX, US
Roy S. HERBST - Houston TX, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
G01N 33/74, A61K 39/395, A61K 31/506, A61K 31/4439, C12Q 1/68, A61K 31/4045
US Classification:
4241331, 435 723, 435 611, 514414, 51425218, 514338
Abstract:
Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and/or who have undergone adjuvant therapy are also provided herein.